- Home
- NXN vs TENX Comparison
NXN vs TENX Comparison
Compare NXN & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXN | TENX |
|---|---|---|
| Founded | 1992 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.3M | 56.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NXN | TENX |
|---|---|---|
| Price | $12.10 | $12.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 9.7K | ★ 180.6K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.64 | $4.63 |
| 52 Week High | $12.45 | $12.42 |
Technical Indicators
Market Signals| Indicator | NXN | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 50.05 | 86.18 |
| Support Level | $11.90 | $10.40 |
| Resistance Level | $12.18 | $10.55 |
| Average True Range (ATR) | 0.11 | 0.77 |
| MACD | -0.01 | 0.27 |
| Stochastic Oscillator | 57.13 | 86.39 |
Price Performance
Historical ComparisonAbout NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.